(PharmaNewsWire.Com, July 14, 2017 ) The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Publisher's analysts forecast the global cancer monoclonal antibodies market to grow at a CAGR of 10.86% during the period 2017-2021. For more information about this report: http://www.reportsweb.com/global-cancer-monoclonal-antibodies-market-2017-2021 . Covered in this report The report covers the present scenario and the growth prospects of the global cancer monoclonal antibodies market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded cancer mAbs and biosimilars used to treat cancer. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography: -Americas -APAC -EMEA
Publisher's report, Global Cancer Monoclonal Antibodies Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
